Kornimate/medical-research-clean huggingface dataset:
the effect of acupressure in hemodialysis patients

Conditions: Fatigue; Comfort; Quality of Life

Summary: this randomized controlled study evaluates the effect of acupressure application on fatigue, quality of life and comfort in hemodialysis patients. in our research, it is aimed to reduce fatigue, increase the quality of life and comfort level in hemodialysis patients with acupressure applied.

in the study, 60 hemodialysis patients were randomly assigned to the study and control groups. the study group (n=30) acupressure is formulated according to the standards of the world health organization and in a certain order to the points of stomach 36 (st 36), gall bladder 34 point (gb 34), spleen 6 point (sp 6) and kidney 1 point (k 1) will be applied. consideration will be given to the appropriate pressure intensity and duration. since the reactions of individuals will be different from each other, the stiffness and pressure will be adjusted according to the sensitivity of the individual in order not to cause tissue damage. pressures will be applied manually by a single practitioner. considering the anatomical area where the point is located, the most suitable thumb, index and/or middle finger will be used for application to the relevant point. successive compressions will be applied at a frequency that does not disturb the patient, does not cause pain, and has a calming effect. considering the studies done, a person will be given acupressure three times a week for four weeks. no intervention will be made to the control group (n=30). in order to avoid ethical problems both groups will be given an informative training on acupressure and fatigue, increase the quality of life and comfort level in hemodialysis patients at the end of the study. the primary outcome of the study is the effect of acupuncture on fatigue in hemodialysis patients. the secondary result of the study is the effect of acupuncture on quality of life and comfort level in hemodialysis patients. the results will be collected before the acupressure and in the 4th week of the last intervention.

Eligibility criteria:
inclusion criteria: * written and verbal consent was obtained to participate in the study, * can read, write, speak and understand turkish, * are older than 18 years, * have received hd treatment for at least 6 months, * receiving hd treatment 3 times a week, * fatigue severity ≥4, using a single-item fatigue index ranging from 0 to 10 points, * absence of lower extremity wounds * any complementary therapy * conscious, fully oriented and cooperative and open to communication, * no visual, hearing and perception problems, * any psychiatric patient exclusion criteria: * wound or amputation of lower extremities, rheumatoid arthritis or limb fracture * any psychiatric disease, * patients with hepatitis b and hepatitis c, * using any of the complementary and integrated methods * those who receive hd treatment twice a week

Keywords: acupressure hemodialysis patients fatigue comfort quality of life
the registry evaluating functional outcomes of resynchronization management

Conditions: Congestive Heart Failure

Summary: the purpose of this study is to evaluate the functional outcomes of resynchronization management and to describe the patient psychosocial characteristics (depression ad anxiety) and associated outcomes with electrophysiologic device therapy for chronic congestive heart failure.

this project will prospectively enroll all consecutive patients undergoing implantable cardioverter defibrillator (icd) and icd with biventricular pacemaker (crt-d) implantation for heart failure from in-patient and out-patient setting. primary objective: compare the psychosocial function and quality of life of icd patients to patients receiving crt-d therapy. secondary outcome objectives: 1)determine and compare the change in lved (left ventricular end distolic) dimension and lvesv (left ventricular end systolic volume)from baseline to 9 month follow up in crt and icd patient.2)determine and compare the change in nyha (new york heart association) classification, kccq, optimisim and pessimism, degree of stress, and social support from baseline to 9 month follow up in crt and icd patients. florida patient acceptance survey and florida shock anxiety scale will be determined and compared at 3 monthe and 9 months.3)determine and compare clinical composite score(packer m 2002)in patient groups where: worsened-patient dies, improved, unchanged. inclusion criteria: patient referred for device therapy (icd or crt-d) for chronic congestive heart failure who are willing and able to give informed consent and participate in follow-up calls. duration of patient follow up will be 9 months. statistical mehtodology: univariate, multivariatae, kaplan-meier analysis

Eligibility criteria:
inclusion criteria: * patients implanted with icd who meet primary prevention (scd-heft or madit ii indications. * patients implanted with crt-d indications (i.e. nyha class iii or iv; qrs \> = to 120ms; lvef \<= to 35%) patient willing to give informed consent and participate in follow up evaluation. exclusion criteria: * non-english speaking patients and patients who are unable to give consent or participate in follow up protocols due to lack of a home phone or unwilling to disclose phone numbers. * patients with significant transient neurological impairment before, during or after device implant who have been deemed incompetent to complete the consent process, or who are unable to participate in follow-up evaluation tests.

Keywords: chf
the added value of quantification of lung function in patients undergoing radiotherapy, using tc-99m-maa spect-ct

Conditions: Lung Cancer

Summary: adult patients referred to radiotherapy treatment of primary or secondary malignant involvement of the lung parenchyma, who are not meeting the exclusion criteria, will be introduced to the study and suggested to participate in it by the radiotherapist, dr viacheslav soyfer, m.d. from the institute of radiotherapy tel aviv (sourasky) medical center. they will sign an informed consent and the study will be conducted based on the agreement of the institutional ethical committee, prior to perfusion study. each patient will be evaluated three times: prior to treatment, a baseline evaluation mid-follow-up period 6 weeks post initiation of radiotherapy and a delayed follow up 6 months post treatment. each spect/ low dose ct assessment will take place within two weeks of the clinical and pft assessment. the study will take place within a duration of two years, from recruiting the participating patients to the completion of the study protocol by the last recruited patient. for the individual patient, the duration of participation is six months. perfusion spect/ low dose ct studies with a non-diagnostic low dose chest ct will be performed after the i.v. injection of 4 mci 99m-tc-maa. spect/ low dose ct scan will be acquired immediately post injection on a ge optima nm/ct 640 camera. in order to obtain a better definition of the irradiated fields, we will co-register the spect/ low dose ct with high-resolution ct provided from the institute of radiotherapy. in this procedure, the low dose chest ct is used as a bridge between high resolution ct and the functional imaging spect. using the q.lung segmentation tool, individual whole lung function and lung subunits will be assessed, and will be correlated to irradiated fields. calculated data for each study step will be compared in order to assess the extent of rt induced lung injury.


Eligibility criteria:
inclusion criteria: * adult patients both female and male above 18 years old referred to radiotherapy treatment of primary or secondary malignant involvement of the lung parenchyma. exclusion criteria: * patients undergoing treatments that might induce lung toxicity other than the rt being assessed will be excluded. * patients suffering of lung illnesses as infection, pulmonary embolism, and congestive heart failure will be excluded. * special populations like pregnant women, children and legally incompetent patients will not be included in this study.
investigation of the safety and efficacy of renzapride in constipation predominant irritable bowel syndrome (ibs)

Conditions: Irritable Bowel Syndrome

Summary: the purpose of the study is to investigate whether renzapride will help alleviate the symptoms associated with constipation predominant irritable bowel syndrome in female patients.

irritable bowel syndrome (ibs) is a chronic gastrointestinal disorder characterized by recurrent symptoms of abdominal pain/discomfort accompanied by disturbed bowel function. in this study female patients with constipation predominant ibs will receive one of two dosing regimens of renzapride or placebo for 12 weeks. patients will record the severity of their symptoms throughout the study. the results will be analysed to see if those patients who received renzapride had greater relief of their symptoms than did the patients who received placebo.

Eligibility criteria:
inclusion criteria: * females with constipation predominant ibs as defined by the rome ii criteria * colonoscopy or sigmoidoscopy in previous 5 years showed no significant disease exclusion criteria: * patients who have diarrhoea predominant or alternating symptom ibs * other gastrointestinal diseases that affect bowel transit

Keywords: irritable bowel syndrome constipation-predominant irritable bowel syndrome
supportive expressive therapy for depressed and anxious adolescents

Conditions: Depression; Anxiety

Summary: the purpose of the study is to investigate the effectiveness of providing supportive expressive therapy to adolescents who are depressed and/or anxious.

supportive expressive therapy (set; a 16 session manualized form of psychodynamic therapy) has been well utilized with adult clients. to date, there is no known systematic study into the benefit of this method of therapy with adolescents who are depressed and/or anxious. it is thought that set would be useful for this population as it is similar in principle to interpersonal relationship therapy (ipt), which has been shown to be effective for use with depressed adults and youth. both ipt and set help clients explore the role they play within challenging relationships in their lives. set, however, allows for the exploration of more relationships within the adolescents' circle. moreover, set explores the adolescents' perceptions of themselves, others, and their wish in relationships. further, the set method is more easily individualized in that it affords greater flexibility in design and possibility for change over time. accordingly, the purpose of this study is to explore the feasibility of utilizing this method of therapy with adolescents who are depressed and anxious. we will be exploring the effectiveness of set through the resolution of depressed and/or anxious adolescents' conflictual relationships thereby reducing their symptomatology.

Eligibility criteria:
inclusion criteria: * 15-24 year old, male \& female adolescents, primary diagnosis of depression or anxiety disorder. * clients with co-morbid diagnoses, suicidal ideation or taking medication would not necessarily be excluded if deemed able to partake in the proposed therapy. * medication dose needs to be stable for 4-6 weeks prior to starting therapy. exclusion criteria: * clients who are actively psychotic, developmentally delayed, or have a diagnosis of bipolar disorder. * clients who are not fluent in english.

Keywords: depression anxiety adolescents treatment supportive expressive therapy
study of cp-675,206 in refractory melanoma

Conditions: Refractory Melanoma

Summary: cp-675,206 is a fully human monoclonal antibody (mab). it binds to the ctla4 molecule, which is expressed on the surface of activated t lymphocytes. cp-675,206 is thought to stimulate patients' immune systems to attack their tumors. cp-675,206 is not expected to have a direct effect on tumor cells. cp-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in phase 1 and phase 2 clinical studies.


Eligibility criteria:
inclusion criteria: * surgically incurable stage iii or iv melanoma * one prior systemic treatment for metastatic melanoma * measurable disease * eastern cooperative oncology group (ecog) ps = 0 or 1 exclusion criteria: * melanoma of ocular origin * received prior vaccine * received prior ctla4-inhibiting agent * history of, or significant risk for, chronic inflammatory or autoimmune disease * potential requirement for systemic corticosteroids

Keywords: refractory melanoma malignant melanoma
menopur® in a gonadotropin-releasing hormone (gnrh) antagonist cycle with single-blastocyst transfer in a high responder subject population

Conditions: Infertility

Summary: the purpose of this trial is to demonstrate non-inferiority of menopur® versus recombinant follicle stimulating hormone (rfsh) (gonal-f®) with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation (cos) following gnrh treatment.


Eligibility criteria:
inclusion criteria: * females aged 21 to 35 years with regular ovulatory menstrual cycles of 21 to 45 days, with a body mass index (bmi) between 18 and 30 kg/m2 who desire pregnancy. * subjects must be high responders, defined as subjects who have a serum anti-müllerian hormone (amh) ≥5 ng/ml at screening. * documented history of infertility (e.g., unable to conceive for at least 12 months or for at least 6 months if receiving donor sperm) with a day 2 or day 3 serum fsh level between 1 and 12 iu/l (inclusive), the results of which should be obtained within 6 months prior to randomization. exclusion criteria: * known stage iii-iv endometriosis (american society for reproductive medicine, 2012). * history of recurrent miscarriage not followed by a live birth (recurrent is defined as two (2) or more consecutive miscarriages). * previous in vitro fertilization (ivf) or assisted reproductive technology (art) failure due to a poor response to gonadotropins. poor response is defined as development of ≤2 mature follicles or history of 2 previous failed cycle cancellations prior to oocytes retrieval due to poor response.
a trial comparing a paclitaxel eluting stent with biodegradable polymer versus a bare metal stent

Conditions: Coronary Artery Disease

Summary: the success of stent implantation has led to the increasingly widespread use of them in the treatment of coronary artery disease (sigwart, serruys, fischman)and although stent restenosis is still a limit for this therapeutic mode (serruys, rodriguez) the new generation of stents with improved coating materials and the development of polymers that release different kinds of drugs that prevent the activation and/or proliferation of smooth muscle cells (ultimate cause of restenosis) (grube, rodriguez). shows major improvements on this matter. the new generation of stents with biodegradable polymers and short time of drug release gives new advantages to this therapeutic, multiple studies and registries challenge this new devices (taxus i and ii, ravel, sirius, eraci ii and iii). for this reason the present study aims to compare a stainless steel stent with a drug eluting stent with coated of biodegradable polymer matrix hemoparin and paclitaxel.

patients with de novo lesions treated in different institutions in buenos aires argentina were randomized to treat with a stainless steel stent ("euca sts flex") or a drug-eluting stent (" euca sts flex de") with a coating of a biodegradable polymer matrix of hemoparin and paclitaxel.

Eligibility criteria:
inclusion criteria: * patient signing informed consent after receiving extensive written and oral information about the trial, * older than 18 years, * agreement to have a control examination done after six months, * patients with angina pectoris symptoms (ccs stages i-iv, unstable angina pectoris braunwald b and c) and patients with documented silent ischemia; * patients with one or more de novo lesions which all are to be dilated in the same session; * target vessel diameter of 2.5 to 4.0 mm exclusion criteria: * female patients of child bearing age with pregnancy suspicion(a pregnancy test will be done in this cases) * acute myocardial infarction (q wave or non q wave ) with documented ck levels more than 2 fold higher than the normal values in the preceding 72 hours , * substantially calcified lesion precluding successful pre dilatation, * ejection fraction less than 35%, * patient with previous pci with one des, * target lesion \< 2.5 mm * coagulopathy or clotting disorders, leucopenia anemia or thrombocytopenia, * allergy, hypersensitivity or adverse reaction to paclitaxel, * intolerance to the clopidogrel, ticlopidine or aspirin or unable to receive clopidogrel for one year, * active duodenal or gastric ulcer, * life expectancy less than 1 year, * patient with lm disease (\>50%)

Keywords: biodegradable polymer drug eluting stent in stent restenosis stent thrombosis bare metal stent
modified atkins diet for overweight and obesity

Conditions: Overweight or Obesity

Summary: the aim of the study is to investigate dynamic changes in biochemical metabolism, gut microbiome and its metabolites among overweight and obese participants while they are on a modified atkins diets.

the mechanisms of obesity are complex, involved in genes, environment, life style, and systemic and adipose tissue inflammation. dysbiosis of gut microbiome is considered to make a difference in obesity. on the other hand, both long-term and short-term dietary interventions can induce changes in the body composition and structure and function of gut microbiome. however, it is not really clear how gut microbiome changes along with weight loss in overweight or obese. in the present study, investigators aim to characterize the gut microbiome among overweight or obese participants on a modified atkins diets. the stool and blood samples were collected by an interval of every 5% and 10% of weight loss, respectively. data collecting mainly covers: 1) body composition analysis ; 2) obesity related biochemical metabolism; 3) measurement of gut microbiome using metagenome and 16s rrna sequencing techniques; 4) metabolomics of serum and gut microbiome; 5) measurement of physical activity and diets using questionnaires.

Eligibility criteria:
inclusion criteria: 1. 18-55 years old; 2. bmi \> 23.9kg/m2; 3. being willing and able to receive guidelines to a modified atkins diet; 4. signed informed consent. exclusion criteria: 1. patients with serious physical and mental diseases (including cardiovascular and cerebrovascular diseases, liver and kidney diseases, respiratory diseases gastrointestinal diseases, mental diseases, etc.); 2. patients with malignant tumor; 3. pregnant and lactating women; 4. those with recent relocation plans.

Keywords: modified atkins diet overweight obesity gut microbiome body composition
a study to see whether two hiv vaccines are safe and can prevent hiv infection

Conditions: HIV Infections; HIV Seronegativity

Summary: the purpose of this study is to see whether an hiv vaccine, alvac vcp205, is safe and can prevent hiv infection. the vcp205 vaccine will be tested with another vaccine, gp160mn/lai-2.

this study consists of 2 parts: part a: dose-escalation protocol using oligomeric gp160mn/lai-2. part b: placebo-controlled, randomized, double-blind (within arm) study of vcp205 priming with gp160mn/lai-2 boosting. volunteers are followed for at least 1 year.

Eligibility criteria:
inclusion criteria volunteers may be eligible for this study if they: * are hiv-negative. * are in good health. * are between ages 18 and 55. * are available for at least 1 year. * are a resident of the united states of america. * agree to practice sexual abstinence or use birth control. exclusion criteria volunteers will not be eligible for this study if they: * have ever been given an hiv vaccine or certain other vaccines. (however, rabies vaccines are allowed.) * participate in activities that place them at high-risk for hiv infection, such as injection drug use or unprotected sex with someone who has hiv infection. * have certain psychiatric, medical, or substance abuse problems. * are allergic to eggs or other vaccines. * are an employee at a participating site and have access to study information. * are taking certain medications. * have received blood transfusions within 3 months before entering this study. * are pregnant or breast-feeding.

Keywords: vaccines, synthetic viral vaccines hiv-1 dose-response relationship, drug hiv envelope protein gp160 aids vaccines hiv seronegativity avipoxvirus immunization hiv envelope protein gp120 recombination, genetic
chest computed tomography (ct) screening study with antibody testing

Conditions: Lung Cancer

Summary: the purpose of this study is to assess the value of earlycdt-lung test and ct scan both in lung cancer detection and potential health economic outcomes.

earlycdt-lung test and ct scan both for lung cancer detection and potential economic outcomes.

Eligibility criteria:
* persons 50-75 * asymptomatic for lung cancer * current or former (stopped smoking less than 10 years ago) cigarette smokers * history of cigarette smoking of at least 20 pack years * history of cigarette smoking with a family history of lung cancer which gives an individual a personal risk similar to a smoking history of 20 pk/years (i.e. 1% at 5 years). * mentally competent individuals to sign an informed consent. * healthy enough to undergo pulmonary resection or stereotactic body radiotherapy. * a fully informed signed consent form must have been obtained.

Keywords: cdt-lung,ct scan,lung cancer detection
the daytime circadian rhythm in exhaled volatile organic compounds in people living without and diabetes

Conditions: Diabetes Mellitus

Summary: exhaled volatile organic compounds will be measured during daytime with the goal to identifying circadian variability. the study incudes three subgroups: people without diabetes, people with type 1 diabetes, and people with type 2 diabetes. a total of 60 people will be recruited for the study.


Eligibility criteria:
inclusion criteria subgroup 1: * age 18 or older * hba1c below 6.5% * written informed consent subgroup 2: * age 18 or older * t1d (type 1 diabetes) with mdi (multiple daily injection) or csii (continuous subcutaneous insulin infusion therapy) therapy \>1 year * written informed consent subgroup 3 * age 18 or older * t2d (type 2 diabetes) with oral antidiabetic medication or insulin therapy * written informed consent exclusion criteria * pregnancy or breastfeeding * smoking (last cigarette less than 6 months ago) * any chronical lung and intestinal disease diagnosis (such as intestinal bowel disease (ibd); asthma; copd (chronic obstructive pulmonary disease); lung cancer, ...) * coeliac disease * lactose and fructose intolerance * any acute disease diagnosis (such as viral or bacterial infection) * drinking habit of more than four units of alcohol per day * current inhaled medicines treatments * antibiotic treatment in the previous 4 months